Why Vicore Pharma Holding AB (publ)’s (VCRE) Stock Is Down 5.04%
As of Monday, August 31, Vicore Pharma Holding AB (publ)’s VCRE share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Vicore Pharma Holding AB (publ) (VCRE)
Vicore Pharma Holding AB (publ) VCRE
$11.59
0.04
0.35%
September 4, 2026 3:59:20 PM
EST
Volume: 14,661
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Commentary & Analysis
Is Vicore Pharma Holding AB (publ) (VCRE) Overvalued?
We dive into why Vicore Pharma Holding AB (publ) (VCRE) could be considered overvalued on 2026-08-24, based on AAII’s Value Score and Grade.Jenna Brashear
Why Vicore Pharma Holding AB (publ)’s (VCRE) Stock Is Down 10.24%
As of Monday, August 24, Vicore Pharma Holding AB (publ)’s VCRE share price has dipped by 10.24%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Vicore Pharma Holding AB (publ)’s (VCRE) Stock Is Down 7.19%
As of Monday, August 17, Vicore Pharma Holding AB (publ)’s VCRE share price has dipped by 7.19%, which has investors questioning if this is right time to buy.Michael Rose
Why Vicore Pharma Holding AB (publ)’s (VCRE) Stock Is Down 12.93%
As of Friday, August 14, Vicore Pharma Holding AB (publ)’s VCRE share price has dipped by 12.93%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | VCRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $320.8 | $282.4 | 32% |
|
| Shares Out (Mil) | 29.0 | 54.0 | 36% |
|
| Institutional Ownership | 87.7% | 93.1% | 55% |
|
| Float (Mil) | 198.6 | 42.2 | 74% |
|
| Beta | 0.12 | 0.94 | 9% |
|
| Avg Daily Volume (000s) | 13 | 482 | 19% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | VCRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (23.7%) | (10.1%) | 17% |
|
| EPS (5yr) | 8.1% | 15.9% | 43 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (32.8%) | (15.6%) | 17% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VCRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 1% |
|
| Net Income (TTM) (Mil) | ($52) | ($43) | 16% |
|
| EPS (TTM) | ($0.197) | ($1.500) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($47) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $216 | $190 | 26% |
|
| Valuation | VCRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 37.39 | 2.84 | 98% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VCRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (52.2%) | (47.7%) | 11% |
|
| ROE | (56.4%) | (55.0%) | 14% |
|
| Liabilities to Assets | 8.2% | 29.8% | 5% |
|
| F-Score | 1 | 3 | 1% |
|
Vicore Pharma Holding AB (publ) did not pass any screens on 9/4/2026.
